Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Phase II Clinical Study Comparing Immunotherapy Combined With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy Maintenance Versus Capecitabine Maintenance in Locally Advanced High-Risk Nasopharyngeal Carcinoma

NCT07392320 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07392320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07392320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Phase II Clinical Study Comparing Immunotherapy Combined With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy Maintenance Versus Capecitabine Maintenance in Locally Advanced High-Risk Nasopharyngeal Carcinoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
February 10, 2026
Completion date
February 10, 2033
Enrollment
142 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharangeal cancer